Sociodemographic, volumetric and clinical characteristics at baseline
| Characteristic | Patients n = 50* | Healthy volunteers n = 50* | Statistical test | p value | Effect size† |
|---|---|---|---|---|---|
| Age, yr | 26 (24–30.25) | 26 (23–30) | t = 992 | 0.07 | d = −0.36 |
| Female | 22 (44%) | 22 (44%) | χ2 = 0.16 | 0.42 | V = 0.08 |
| Relative volume, mL | |||||
| Left hippocampus | 2.64 ± 0.27 | 2.77 ± 0.35 | t = −3.63 | 0.047 | d = −0.42 |
| Right hippocampus | 2.78 ± 0.31 | 2.84 ± 0.36 | t = −2.13 | 0.048 | d = −0.18 |
| Left amygdala | 1.01 ± 0.14 | 1.11 ± 0.14 | t = −4.26 | 0.001 | d = −0.71 |
| Right amygdala | 1.14 ± 0.15 | 1.24 ± 0.14 | t = −4.32 | 0.001 | d = −0.69 |
| Duration of untreated psychosis, d | 31 (8–115) | — | — | — | — |
| Cannabis user | 29 (58%) | — | — | — | — |
| Tobacco use, cigarettes/d | 4.5 (0–14) | — | — | — | — |
| Diagnosis | |||||
| Schizophreniform disorder | 18 (36%) | — | — | — | — |
| Psychosis not otherwise specified | 28 (56%) | — | — | — | — |
| Brief psychotic disorder | 4 (8%) | — | — | — | — |
| Benzodiazepine treatment | 43 (86%) | — | — | — | — |
| BDNF, pg/mL | 45.27 ± 27.14 | — | — | — | — |
| PANSS positive subscale score | 24.88 ± 6.74 | — | — | — | — |
| PANSS negative subscale score | 16.86 ± 6.65 | — | — | — | — |
| PANSS general pathology score | 43.68 ± 8.27 | — | — | — | — |
| PANSS total score | 85.24 ± 15.76 | — | — | — | — |
| CDSS score | 1.22 ± 2.02 | — | — | — | — |
| GAF score | 29.7 ± 8.89 | — | — | — | — |